TARS - Tarsus Pharma presents new Saturn-1 trial data and Titan study results at ASCRS 2021

Yuliya Starikova/iStock via Getty Images Tarsus Pharmaceuticals (TARS) announces new data from its Saturn-1 Phase 2b/3 trial and the Titan real-world collarette prevalence study at the ASCRS 2021 Annual Meeting. The new Saturn-1 data reinforce the strong potential clinical utility of TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis, with a broad range of patients showing a substantial response. New Saturn-1 data demonstrated that, in addition to achieving all primary and secondary endpoints, the results showed a strong patient responder rate. Results showed meaningful improvement in the number of mites per lash as well as collarette grade reduction: 95% of TP-03 patients showed a significant response in mite count, achieving ?0.5 mites per lash at day 43 from an average baseline of 3.2 mites per lash, compared to 36% of those on vehicle (p<0.0001), with statistically significant results seen as early as day 15. 93% of TP-03

For further details see:

Tarsus Pharma presents new Saturn-1 trial data and Titan study results at ASCRS 2021